GSA Capital Partners LLP Has $378,000 Holdings in Guardant Health, Inc. (NASDAQ:GH)

GSA Capital Partners LLP trimmed its stake in Guardant Health, Inc. (NASDAQ:GH) by 13.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,489 shares of the company’s stock after selling 2,510 shares during the period. GSA Capital Partners LLP’s holdings in Guardant Health were worth $378,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GH. JNBA Financial Advisors bought a new stake in shares of Guardant Health during the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new position in shares of Guardant Health during the 3rd quarter worth approximately $34,000. Quarry LP bought a new stake in shares of Guardant Health in the 2nd quarter valued at $44,000. Canton Hathaway LLC acquired a new position in shares of Guardant Health during the 2nd quarter valued at $59,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Guardant Health during the second quarter worth $71,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Trading Up 1.3 %

Shares of GH stock opened at $31.09 on Friday. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $37.04. The company has a quick ratio of 5.85, a current ratio of 6.22 and a debt-to-equity ratio of 16.70. The company has a 50 day moving average of $24.00 and a 200-day moving average of $26.71. The firm has a market cap of $3.84 billion, a P/E ratio of -7.31 and a beta of 1.11.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company’s revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.73) EPS. Sell-side analysts anticipate that Guardant Health, Inc. will post -3.38 earnings per share for the current year.

Insider Buying and Selling at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares in the company, valued at approximately $228,675.20. This represents a 27.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

GH has been the topic of a number of research analyst reports. TD Cowen increased their price objective on shares of Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Sanford C. Bernstein lowered their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. Leerink Partners reduced their price objective on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Citigroup raised their price target on shares of Guardant Health from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, The Goldman Sachs Group boosted their price objective on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $40.60.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.